Lichen Simplex Chronicus
Conditions
Keywords
PG-033, Lichen Simplex Chronicus, Pruritus
Brief summary
The goal of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) profiles of single ascending oral doses(SAD) of PG-033 by directly comparing it with placebo. Meanwhile, the impact of a high-fat meal on the pharmacokinetics of PG-033 will also be evaluated. The research will also explore the potential metabolites and metabolic pathways of PG-033 within the human body，as well as investigate the effect of PG-033 on the QTc interval.
Detailed description
This is a single-center, randomized, double-blind, placebo-controlled, single-dose administration, and dose escalation phase I clinical study in adult participants aged from 18 to 45 years old (including threshold) with healthy male and female subjects. The study includs a single dose ascending study (SAD) and a food effect (FE) study. The single ascending dose (SAD) study will be conducted by increasing the dosage from low dosage level to high. Approximately 40 participants will be randomized 3:1 to PG-033 or placebo in 5 dose groups. The food effect study adopts a single-center, randomized, open-label, single-dose, two-period and two-sequence crossover clinical trial design. 12 participants will be randomly divided into group A and group B, with 6 participants in each group. In the first period, the 6 subjects in Group A will take PG-033 on an empty stomach, while the 6 subjects in Group B will take PG-033 after having a high-fat meal. In the second period, the two groups will cross over in taking the drug. That is, the subjects in Group A will take PG-033 after having a high-fat meal, and the subjects in Group B will take PG-033 on an empty stomach. The washout period between the two dosing periods is 7 days.
Interventions
DRUGPG-033
Oral tablets (2mg， 10mg)
Oral tablets (2 mg, 10 mg) (matching corresponding study medication)
Sponsors
Prime Gene Therapeutics Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* 1\. Read, understood, and signed an ICF before any investigational procedure(s) are performed. 2.Male or female aged 18 to 45 (including threshold). 3. For male subjects, the body weight should be ≥ 50.0 kg, and for female subjects, the body weight should be ≥ 45.0 kg. The body mass index (BMI) should be within the range of 19.0 to 26.0 kg/m²(including threshold). 4\. Results of vital signs examination, physical examination, clinical laboratory tests (including blood routine examination, urine routine examination, blood biochemistry examination, coagulation function examination, thyroid function examination, etc.), chest X-ray, adrenal gland color ultrasound, etc. during the screening period show normal results or, if there are abnormalities, they are judged by the investigator to have no clinical significance. 5\. Be willing to avoid pregnancy or voluntarily take effective contraceptive measures and have no sperm or egg donation plan from the signing of the informed consent form to three month after the last administration of the investigational medicinal product. 6\. Be able to communicate well with the investigator and understand and comply with the requirements of the study.
Exclusion criteria
* 1\. Participants with abnormal electrocardiogram results during screening (e.g., QT/QTcF \> 440 ms, PR interval \> 200 ms, QRS complex duration \> 100 ms, clinically significant abnormalities of the P wave, clinically significant changes in the ST-T wave, etc.). 2\. Participants known to be allergic to this product or related excipients; or participants with an allergic constitution (such as those who are allergic to two or more drugs or foods). 3\. Participants with a history of chronic diseases or severe diseases in the circulatory, urinary, respiratory, hematological and lymphatic, endocrine, immune, mental and neurological, digestive systems, etc. 4\. Participants who have undergone major surgery within 6 months before the first dose administration, or those who plan to have surgery during the study period, or those who have undergone surgery that, as judged by the investigator, will affect the evaluation of the drug's safety and pharmacokinetic characteristics. 5\. Participants who have used any drugs (including any prescription drugs, over-the-counter drugs, traditional Chinese herbal medicines) and health products within 2 weeks before the first dose administration. 6\. Participants who have used any drugs that inhibit or induce the liver's metabolism of drugs (e.g., barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole, selective serotonin reuptake inhibitors (SSRI) antidepressants, cimetidine, diltiazem, macrolides, nitroimidazoles, sedative-hypnotics, verapamil, fluoroquinolones, antihistamines, etc.) within 4 weeks before the first dose administration. 7\. Participants who are unable to stop consuming beverages and foods containing caffeine, alcohol, etc. (including chocolate, tea, coffee, cola, etc.), or foods that affect drug metabolism such as grapefruit, grapefruit products, pitaya, mango, pomelo, etc. from 48 hours before the first dose administration until the end of the trial, or those who are unable to stop consuming the above-mentioned diets from 48 hours before the first dose administration until the end of the trial. 8\. Participants who have received live attenuated vaccine vaccination within 4 weeks before the first dose administration or those who need to receive live attenuated vaccine vaccination during the trial. 9\. Participants with positive serological results for hepatitis B surface antigen (HBsAg), hepatitis C antibody, Treponema pallidum antibody, or human immunodeficiency virus antibody during screening. 10\. Participants who have participated in other clinical trials within 3 months before the first dose administration. 11\. Participants who have donated blood or lost a total of ≥ 400 mL of blood (excluding physiological blood loss in females) within 3 months before the first dose administration, received blood transfusion or used blood products, or those who plan to donate blood during the trial or within 1 month (30 days) after the end of the trial. 12\. Participants who have consumed an average of more than 2 units of alcohol per day within 30 days before screening (1 unit ≈ 360 mL of beer or 45 mL of liquor with an alcohol content of 40% or 150 mL of wine), or those who cannot abstain from alcohol during the trial, or those with a positive result in the alcohol breath test. 13\. Participants who have smoked an average of more than 5 cigarettes per day within 3 months before screening, or those who cannot stop smoking during the trial. 14\. Participants with a history of drug abuse within 1 year before screening or those who tested positive for drug abuse screening. 15\. Participants who cannot tolerate intravenous puncture/indwelling needle or those with a history of fainting at the sight of needles or blood. 16\. Participants with special dietary requirements and who cannot accept the unified diet. 17\. Pregnant or lactating women; 18. Other participants determined by the investigator to be unsuitable for participation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety and tolerability of PG-033 tablets | Single Ascending Dose study: 7 days；Food Effect study: 14 days | Incidence of treatment-emergent adverse events (AEs) and serious adverse events (SAEs) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics parameter: Cmax | up to 3 days | Maximum Observed Plasma concentration (Cmax) |
| Pharmacokinetics Parameter:Tmax | up to 3 days | Time at which the maximum plasma concentration (Cmax) occurs |
| Pharmacokinetics parameter: AUC0-t | up to 3 days | Area under the plasma concentration-time curve from dosing (time zero） to the time of the last measured concentration |
| Pharmacokinetics parameter: AUC0-∞ | up to 3 days | Area Under the Plasma Concentration Versus Time Curve from Zero Extrapolated to Infinity (AUC0-∞） |
| Pharmacokinetics parameter: t1/2 | up to 3 days | Terminal Elimination Half-Life (t1/2) |
| Pharmacokinetics parameter: Vd/F | up to 3 days | Volume of Distribution (Vd/F) |
| Pharmacokinetics parameter: CL/F | up to 3 days | Total Body Clearance |
| Pharmacokinetics parameter: λZ | up to 3 days | Elimination rate constant (λz) |
| Pharmacokinetics parameter: MRT | up to 3 days | Mean retention time (MRT) |
| Corrected QT interval | up to 24 hours post-dose | Change in QT interval corrected for heart rate (QTc) interval from baseline |
Countries
China
Contacts
CONTACTXiaohua Hao Beijing Shijitan Hospital Affiliated to Capital Medical Univer
Outcome results
None listed